<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71137</article-id><article-id pub-id-type="doi">10.7554/eLife.71137</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-243518"><name><surname>Kimura</surname><given-names>Hirokazu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243519"><name><surname>Paranal</surname><given-names>Raymond M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/></contrib><contrib contrib-type="author" id="author-263996"><name><surname>Nanda</surname><given-names>Neha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243520"><name><surname>Wood</surname><given-names>Laura D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243521"><name><surname>Eshleman</surname><given-names>James R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35604"><name><surname>Hruban</surname><given-names>Ralph H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-95645"><name><surname>Goggins</surname><given-names>Michael G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243522"><name><surname>Klein</surname><given-names>Alison P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>The Familial Pancreatic Cancer Genome Sequencing Project<contrib-group><contrib><name><surname>Brand</surname><given-names>Randall</given-names></name><aff><institution>Department of Medicine, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Cote</surname><given-names>Michele L</given-names></name><aff><institution>Karmanos Cancer Institute, Wayne State University School of Medicine</institution><addr-line><named-content content-type="city">Detroit</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Du</surname><given-names>Mengmeng</given-names></name><aff><institution>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Eshleman</surname><given-names>James R</given-names></name><aff><institution>The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff><institution>Department of Oncology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff><institution>Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Gallinger</surname><given-names>Steven</given-names></name><aff><institution>Ontario Institute for Cancer Research</institution><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff></contrib><contrib><name><surname>Goggins</surname><given-names>Michael</given-names></name><aff><institution>The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff><institution>Department of Oncology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Hruban</surname><given-names>Ralph H</given-names></name><aff><institution>The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff><institution>Department of Oncology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Klein</surname><given-names>Alison P</given-names></name><aff><institution>The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff><institution>Department of Oncology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff><institution>Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Kurtz</surname><given-names>Robert C</given-names></name><aff><institution>Department of Medicine, Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Petersen</surname><given-names>Gloria M</given-names></name><aff><institution>Department of Health Sciences Research, Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Roberts</surname><given-names>Nicholas J</given-names></name><aff><institution>The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff><institution>Department of Oncology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Rustgi</surname><given-names>Anil K</given-names></name><aff><institution>Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Schwartz</surname><given-names>Ann G</given-names></name><aff><institution>Karmanos Cancer Institute, Wayne State University School of Medicine</institution><addr-line><named-content content-type="city">Detroit</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Stoffel</surname><given-names>Elena M</given-names></name><aff><institution>Department of Internal Medicine, University of Michigan</institution><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Syngal</surname><given-names>Sapna</given-names></name><aff><institution>Dana-Farber Cancer Institute and Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib><name><surname>Zogopoulos</surname><given-names>George</given-names></name><aff><institution>The Research Institute of the McGill University Health Centre</institution><addr-line><named-content content-type="city">Quebec</named-content></addr-line><country>Canada</country></aff></contrib></contrib-group></collab><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-222900"><name><surname>Roberts</surname><given-names>Nicholas J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8709-0664</contrib-id><email>nrobert8@jhmi.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Human Genetics Predoctoral Training Program, the McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Oncology, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lou</surname><given-names>Emil</given-names></name><role>Reviewing Editor</role><aff><institution>University of Minnesota</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>El-Deiry</surname><given-names>Wafik S</given-names></name><role>Senior Editor</role><aff><institution>Brown University</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>10</day><month>01</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e71137</elocation-id><history><date date-type="received" iso-8601-date="2021-06-09"><day>09</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-06"><day>06</day><month>01</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Kimura et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Kimura et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-71137-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-71137-figures-v2.pdf"/><abstract><p>Pathogenic germline <italic>CDKN2A</italic> variants are associated with an increased risk of pancreatic ductal adenocarcinoma (PDAC). <italic>CDKN2A</italic> variants of uncertain significance (VUSs) are reported in up to 4.3% of patients with PDAC and result in significant uncertainty for patients and their family members as an unknown fraction are functionally deleterious, and therefore, likely pathogenic. Functional characterization of <italic>CDKN2A</italic> VUSs is needed to reclassify variants and inform clinical management. Twenty-nine germline <italic>CDKN2A</italic> VUSs previously reported in patients with PDAC or in ClinVar were evaluated using a validated in vitro cell proliferation assay. Twelve of the 29 <italic>CDKN2A</italic> VUSs were functionally deleterious (11 VUSs) or potentially functionally deleterious (1 VUS) and were reclassified as likely pathogenic variants. Thus, over 40% of <italic>CDKN2A</italic> VUSs identified in patients with PDAC are functionally deleterious and likely pathogenic. When incorporating VUSs found to be functionally deleterious, and reclassified as likely pathogenic, the prevalence of pathogenic/likely pathogenic <italic>CDKN2A</italic> in patients with PDAC reported in the published literature is increased to up to 4.1% of patients, depending on family history. Therefore, <italic>CDKN2A</italic> VUSs may play a significant, unappreciated role in risk of pancreatic cancer. These findings have significant implications for the counselling and care of patients and their relatives.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>pancreas</kwd><kwd>cancer</kwd><kwd>familial cancer</kwd><kwd>CDKN2A</kwd><kwd>variant of uncertain significance</kwd><kwd>pancreatic ductal adenocarcinoma</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>The Sol Goldman Pancreatic Cancer Research Center</institution></institution-wrap></funding-source><award-id>Pilot Grant</award-id><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>The Rolfe Pancreatic Cancer Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P50 CA622924</award-id><principal-award-recipient><name><surname>Klein</surname><given-names>Alison P</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>The Japanese Society of Gastroenterology</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kimura</surname><given-names>Hirokazu</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>The Japan Society for Promotion of Science</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kimura</surname><given-names>Hirokazu</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>The Joseph C Monastra Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>The Geral O Mann Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Art Creates Cures Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Susan Wojcicki and Denis Troper</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>S10 OD026859</award-id><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Over 40% of <italic>CDKN2A</italic> variants of uncertain significance identified in patients with pancreatic cancer are functionally deleterious and can be reclassified as likely pathogenic with implications for care of patients and their relatives.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a median survival of less than 6 months and a 5-year survival rate of only 10% (<xref ref-type="bibr" rid="bib26">Siegel et al., 2020</xref>). Surveillance of high-risk individuals (HRIs), such as people with a pathogenic germline variant in a pancreatic cancer susceptibility gene, for example, <italic>ATM</italic>, <italic>BRCA1</italic>, <italic>BRCA2</italic>, <italic>CDKN2A</italic>, <italic>CPA1</italic>, <italic>CPB1</italic>, <italic>MLH1</italic>, <italic>MSH2</italic>, <italic>MSH6</italic>, <italic>PALB2</italic>, <italic>PMS2</italic>, <italic>PRSS1</italic>, and <italic>STK11</italic>, has the potential to reduce mortality through detection of early, potentially curable, PDAC and its precursor lesions (<xref ref-type="bibr" rid="bib5">Canto et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Vasen et al., 2016</xref>). The International Cancer of the Pancreas Screening (CAPS) Consortium trials found that surveillance identified either PDAC or a high-grade precursor lesion in 6.8% of HRIs, including relatives of patients with familial pancreatic cancer and individuals with a pathogenic germline variant in a pancreatic cancer susceptibility gene, during a median follow-up 5.6 years (24 of 354 individuals) (<xref ref-type="bibr" rid="bib4">Canto et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Goggins et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Canto et al., 2018</xref>). Similarly, in a recent screening study of 178 HRIs with a germline pathogenic <italic>CDKN2A</italic> variant, 13 individuals with PDAC were identified (7.3%) during a median follow-up 53 months (<xref ref-type="bibr" rid="bib32">Vasen et al., 2016</xref>). Importantly, the overall resection rate and 5-year survival rate was 75% and 24%, respectively (<xref ref-type="bibr" rid="bib32">Vasen et al., 2016</xref>). Furthermore, patients with PDAC and a pathogenic germline variant in a pancreatic cancer susceptibility gene may have cancers that are uniquely sensitive to specific anti-cancer therapies, as is the case for poly(ADP)-ribose polymerase inhibitors and immunotherapy (<xref ref-type="bibr" rid="bib14">Kaufman et al., 2015</xref>; <xref ref-type="bibr" rid="bib16">Le et al., 2015</xref>). Consequently, recent American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines recommend germline testing of all pancreatic cancer patients and their at-risk first-degree relatives (<xref ref-type="bibr" rid="bib8">Goggins et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Stoffel et al., 2019</xref>).</p><p>The <italic>CDKN2A</italic> gene encodes two proteins, p16<sup>INK4a</sup> and p14<sup>ARF</sup>. p16<sup>INK4a</sup> inhibits CDK4 activity, is a regulator of cell cycle progression, and a tumor suppressor gene (<xref ref-type="bibr" rid="bib24">Serrano et al., 1993</xref>). Germline variants in <italic>CDKN2A</italic> that affect p16<sup>INK4a</sup> (hereafter referred to <italic>CDKN2A</italic> variants) can be classified as either pathogenic, benign, or variants of uncertain significance (VUSs) based on American College of Medical Genetics (ACMG) guidelines (<xref ref-type="bibr" rid="bib22">Richards et al., 2015</xref>). Pathogenic germline <italic>CDKN2A</italic> variants have been identified in up to 3.3% patients with familial pancreatic cancer and up to 2.6% of patients with PDAC unselected for family history or without a family history of PDAC (<xref ref-type="bibr" rid="bib2">Brand et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Chaffee et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Hu et al., 2018</xref>; <xref ref-type="bibr" rid="bib15">Kimura et al., 2021</xref>; <xref ref-type="bibr" rid="bib17">Lowery et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">McWilliams et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">McWilliams et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Roberts et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Shindo et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">Singhi et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Zhen et al., 2015</xref>). Strikingly, individuals with a known pathogenic germline <italic>CDKN2A</italic> variant have up to a 12.3-fold increased risk of developing PDAC (<xref ref-type="bibr" rid="bib11">Hu et al., 2018</xref>).</p><p>Germline <italic>CDKN2A</italic> VUSs are a common finding in patients undergoing germline genetic testing. <italic>CDKN2A</italic> VUSs, predominantly rare missense variants, are found in 2.9–4.3% of patients with PDAC, depending on family history (<xref ref-type="bibr" rid="bib6">Chaffee et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">McWilliams et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Roberts et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Shindo et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Zhen et al., 2015</xref>). Finding a germline <italic>CDKN2A</italic> VUS can be a cause of significant clinical uncertainty. For example, while individuals with a pathogenic germline <italic>CDKN2A</italic> variant are recommended for clinical surveillance, those with a germline <italic>CDKN2A</italic> VUS are often not included in surveillance studies unless they fulfill family history criteria (<xref ref-type="bibr" rid="bib8">Goggins et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Stoffel et al., 2019</xref>). Therefore, the functional characterization and reclassification of <italic>CDKN2A</italic> VUSs will inform disease surveillance and early detection efforts.</p><p>The effect of <italic>CDKN2A</italic> variants can be determined in vitro by assay of a specific molecular function of p16<sup>INK4A</sup>, such as binding to CDK4/6, or by assay a broad cellular function, such as cell proliferation, cell viability, and cell cycle progression (<xref ref-type="bibr" rid="bib13">Kannengiesser et al., 2009</xref>; <xref ref-type="bibr" rid="bib20">Miller et al., 2011</xref>; <xref ref-type="bibr" rid="bib21">Ng et al., 2018</xref>). The positive and negative predictive values for assays of broad cellular function are higher than those considering only CDK4/6 binding (<xref ref-type="bibr" rid="bib20">Miller et al., 2011</xref>). For example, some <italic>CDKN2A</italic> variants, such as p.Gly35Ala, p.Gly67Arg, p.Glu69Gly, and p.Arg87Trp, bind to CDK4 comparably to wild type (WT) p16<sup>INK4a</sup>, but do not inhibit cell proliferation, indicating that additional functions not assessed in vitro CDK4 binding are important for cellular function (<xref ref-type="bibr" rid="bib13">Kannengiesser et al., 2009</xref>).</p><p>In this study, we used a validated in vitro cell proliferation assay and cell cycle analysis to determine the functional consequence of <italic>CDKN2A</italic> variants and reclassify 29 germline <italic>CDKN2A</italic> VUSs previously reported in patients with PDAC.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>CDKN2A</italic> variants assayed</title><p>The germline <italic>CDKN2A</italic> variants functionally characterized in this study are presented in <xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Variants were classified using ACMG variant classification guidelines and given as amino acid change with reference to NP_000068.1 (<xref ref-type="bibr" rid="bib22">Richards et al., 2015</xref>). We defined benchmark pathogenic variants as variants previously reported in patients with familial pancreatic cancer, PDAC, or reported in ClinVar as pathogenic or likely pathogenic. Benchmark pathogenic variants included: p.Leu16Arg, p.Arg24Pro, p.Ile49Thr, p.Met53Ile, p.Leu78Hisfs*41, p.His83Tyr, p.Asp84Asn, p.Gly101Trp, and p.Val126Asp (<xref ref-type="bibr" rid="bib6">Chaffee et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Chang et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Horn et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Hu et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">McWilliams et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Roberts et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Zhen et al., 2015</xref>). We defined benchmark benign variants as variants reported in ClinVar as benign or likely benign. Benchmark benign variants included: p.Ala57Val, p.Ala100Ser, p.His123Gln, p.Ala127Ser, p.Arg144Cys, and p.Ala148Thr (<xref ref-type="bibr" rid="bib19">McWilliams et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Roberts et al., 2016</xref>). Germline <italic>CDKN2A</italic> VUSs were selected as detailed in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Briefly, 29 missense <italic>CDKN2A</italic> variants affecting p16<sup>INK4A</sup> that were previously reported in patients with familial pancreatic cancer, PDAC, or reported in ClinVar as VUSs were selected (<xref ref-type="bibr" rid="bib6">Chaffee et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Hu et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">McWilliams et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Roberts et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Shindo et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Zhen et al., 2015</xref>). These 29 VUSs included: p.Met9Thr, p.Pro11Leu, p.Thr18Pro, p.Ala20Gly, p.Arg24Gln, p.Pro41Gln, p.Gln50Arg, p.Leu65Pro, p.His66Pro, p.His66Arg, p.Gly67Arg, p.Ala68Val, p.Glu69Gly, p.Asp74Ala, p.Asp74His, p. Asp84Ala, p.Gly89Asp, p.Arg99Gly, p.Gly101Arg, p.Ala109Pro, p.Gly111Ser, p.Gly122Val, p.Arg124Cys, p.Asp125His, p.Ala127Pro, p.Arg128Pro, p.Ala134Thr, p.Gly139Arg, and p.Ala143Thr.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title><italic>CDKN2A</italic> variants assayed.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Classification<sup>a</sup></th><th align="left" valign="bottom">Variant<sup>b</sup></th></tr></thead><tbody><tr><td align="left" valign="bottom">Pathogenic</td><td align="left" valign="bottom">p.Leu16Arg, p.Arg24Pro, p.Met53Ile, p.Gly101Trp, p.Val126Asp</td></tr><tr><td align="left" valign="bottom">Likely pathogenic</td><td align="left" valign="bottom">p.Ile49Thr, p.Leu78Hisfs*41, p.His83Tyr, p.Asp84Asn</td></tr><tr><td align="left" valign="bottom">Likely benign</td><td align="left" valign="bottom">p.Ala57Val, p.Ala100Ser, p.His123Gln, p.Ala127Ser, p.Arg144Cys</td></tr><tr><td align="left" valign="bottom">Benign</td><td align="left" valign="bottom">p.Ala148Thr</td></tr><tr><td align="left" valign="bottom">VUS</td><td align="left" valign="bottom">p.Met9Thr, p.Pro11Leu, p.Thr18Pro, p.Ala20Gly, p.Arg24Gln, p.Pro41Gln, p.Gln50Arg, p.Leu65Pro, p.His66Pro, p.His66Arg, p.Gly67Arg, p.Ala68Val, p.GluE69Gly, p.Asp74Ala, p.Asp74His, p. Asp84Ala, p.Gly89Asp, p.Arg99Gly, p.Gly101Arg, p.Ala109Pro, p.Gly111Ser, p.Gly122Val, p.Arg124Cys, p.Asp125His, p.Ala127Pro, p.Arg128Pro, p.Ala134Thr, p.Gly139Arg, and p.Ala143Thr</td></tr></tbody></table><table-wrap-foot><fn><p>a. Classification using American College of Medical Genetics (ACMG) variant classification guidelines.</p></fn><fn><p>b. Variant given as protein change with reference to NP_000068.1. Known pathogenic and benign variants used for benchmarking indicated in bold.</p></fn></table-wrap-foot></table-wrap><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Identification of germline <italic>CDKN2A</italic> variant of uncertain significance (VUS) for functional characterization.</title><p>Workflow to identify the 29 germline <italic>CDKN2A</italic> VUS selected for characterization in our functional assay. CDKN2A VUSs were classified using American College of Medical Genetics (ACMG) guidelines and either identified in patients with pancreatic ductal adenocarcinoma (PDAC) from published literature or in ClinVar.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig1-v2.tif"/></fig></sec><sec id="s2-2"><title>Validation of in vitro functional assay</title><p>PANC-1 (CRL-1469) is a human PDAC cell line with a homozygous deletion of <italic>CDKN2A</italic> (<xref ref-type="bibr" rid="bib3">Caldas et al., 1994</xref>). Consistent with previous reports, CDKN2A (p16<sup>INK4A</sup>) was not detectable in PANC-1 cells by western blot (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Stable expression of WT CDKN2A in PANC-1 cells through lentiviral transduction resulted in a significant reduction in cell proliferation compared to empty vector control (p-value &lt; 0.0001) (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Conversely, stable expression of three known pathogenic, and therefore functionally deleterious, <italic>CDKN2A</italic> variants, p. Leu78Hisfs*41, p.Gly101Trp, or p.Val126Asp, in PANC-1 cells resulted in no reduction in cell proliferation compared to the empty vector control (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Development and validation of functional assay.</title><p>(<bold>A</bold>) Western blot of whole cell lysates from PANC-1 cells and PANC-1 cells stably expressing wild type CDKN2A (p16<sup>INK4A</sup>) or selected pathogenic variants using anti-CDKN2A and anti-vinculin antibodies as a loading control. No expression of CDKN2A (p16<sup>INK4A</sup>) detected in PANC-1 cells or PANC-1 cell stably expressing empty vector. CDKN2A (p16<sup>INK4A</sup>) expression detected in PANC-1 cells stably expressing pathogenic variants. (<bold>B</bold>) Growth of PANC-1 cell and PANC-1 cells stably expressing wild type CDKN2A cDNA (p16<sup>INK4A</sup>) or selected pathogenic variants over 14 days in culture. Cell proliferation values are shown as mean (n = 3) ± s.d. normalized to PANC-1 cell stably expressed with empty vector. Significant growth inhibition in PANC-1 cell stably expressing wild type CDKN2A (p16<sup>INK4A</sup>). *p &lt; 0.01. Original files of the full raw unedited blots and the uncropped blots with the relevant CDKN2A and vinculin bands presented in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref> and 3. For raw data in <xref ref-type="fig" rid="fig2">Figure 2</xref>, please refer to <xref ref-type="supplementary-material" rid="fig2sdata4">Figure 2—source data 4</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original file of the full raw unedited CDKN2A blot.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71137-fig2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original file of the full raw unedited vinculin blot.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71137-fig2-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>The uncropped blots with the relevant CDKN2A and vinculin bands labelled.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71137-fig2-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Raw data in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-fig2-data4-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig2-v2.tif"/></fig><p>To establish benchmarks for the functional interpretation of <italic>CDKN2A</italic> VUSs, we next determined cell proliferation values for an additional six known pathogenic and six known benign variants in our assay. Known pathogenic and benign variants are likely functionally deleterious and functionally neutral, respectively, in our assay and were used as benchmarks for interpretation of <italic>CDKN2A</italic> VUSs. The mean cell proliferation value for all pathogenic variants assayed was 0.90 (range: 0.84–1.03), while the mean cell proliferation value for all benign variants assayed was 0.26 (range: 0.14–0.48) (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Importantly, there was clear demarcation between the mean cell proliferations values of assayed benchmark pathogenic and benign variants. Therefore, we set the following thresholds to characterize assayed VUSs. VUSs were characterized as either functionally deleterious or functionally neutral if they had mean cell proliferation values of &gt;0.81 or ˂0.44, respectively, based on the Z-score 95% confidence interval (CI). To classify assayed VUSs with mean cell proliferations values ≥0.44 but ≤0.81, we used a cutoff of 0.66, the midpoint between the lowest mean cell proliferation value for a pathogenic variant and the highest mean cell proliferation value for a benign variant, as area under the receiver operating characteristic (ROC) curve was 1, indicating that our assay could distinguish between pathogenic and benign variants with &gt;99% sensitivity and &gt;99% specificity. Therefore, assayed VUSs with a mean cell proliferation value &gt;0.66 and ≤0.81 were classified as potentially functionally deleterious, while VUSs with a mean cell proliferation value &gt;0.44 than ≤0.66 classified as potentially functionally neutral (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Functional characterization of <italic>CDKN2A</italic> variants.</title><p>Functional characterization of 45 <italic>CDKN2A</italic> variants (9 pathogenic variants, 7 benign variants, 29 variants of uncertain significance [VUSs]) in PANC-1 cells. Cell proliferation values are shown as mean (n = 3) ± s.d. normalized to PANC-1 cell stably expressed with empty vector. Assayed variants with mean cell proliferation values: (1) above the gray shaded area (&gt;0.81) were classified as functionally deleterious, (2) below the gray shaded area (&lt;0.44) were classified as functionally benign, (3) in the gray area above the threshold dotted line (≥0.66 but ≤0.81) were potentially functionally deleterious, and (4) in the gray area below the threshold dotted line (&lt;0.66 but ≥0.44) were potentially functionally neutral. For raw data in this figure, please refer to <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw data in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>CDKN2A expression in human pancreatic ductal adenocarcinoma (PDAC) cells.</title><p>Western blot of whole cell lysates from 293T cells, a human embryonic kidney cell line and PANC-1, MIA PaCa-2, and AsPC-1 cells, human PDAC cell lines using anti-CDKN2A and anti-vinculin antibodies as a loading control. No expression of CDKN2A (p16<sup>INK4A</sup>) detected in human PDAC cells. CDKN2A (p16<sup>INK4A</sup>) expression detected in 293T cells. For the original files of the full raw unedited blots and figures with the uncropped blots with the relevant bands clearly labelled, please refer to <xref ref-type="supplementary-material" rid="fig3s1sdata1">Figure 3—figure supplement 1—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig3s1sdata2">Figure 3—figure supplement 1—source data 2</xref>, <xref ref-type="supplementary-material" rid="fig3s1sdata3">Figure 3—figure supplement 1—source data 3</xref>.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Original file of the full raw unedited CDKN2A western blot.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71137-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Original file of the full raw unedited vinculin western blot.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71137-fig3-figsupp1-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata3"><label>Figure 3—figure supplement 1—source data 3.</label><caption><title>The uncropped western blots with the relevant CDKN2A and vinculin bands labelled.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71137-fig3-figsupp1-data3-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Functional characterization of <italic>CDKN2A</italic> variants in MIA PaCa-2 and AsPC-1 cells.</title><p>Functional characterization of 45 <italic>CDKN2A</italic> variants (9 pathogenic variants, 7 benign variants, 29 variants of uncertain significance [VUSs]). Cell proliferation values are shown as mean (n = 3) ± s.d. normalized to MIA PaCa-2 (<bold>A</bold>) or AsPc-1 (<bold>B</bold>) cell stably expressed with empty vector. Assayed variants with mean cell proliferation values: (1) above the gray shaded area (&gt;0.80 for MIA PaCa-2 cells and 0.91 for AsPC-1 cells) were classified as functionally deleterious, (2) below the gray shaded area (&lt;0.45 for MIA PaCa-2 cells and 0.51 for AsPC-1 cells) were classified as functionally benign, (3) in the gray area above the threshold dotted line (≥0.57 but ≤0.80 for MIA PaCa-2 cells and ≥0.74 but ≤0.91 for AsPC-1 cells) were potentially functionally deleterious, and (4) in the gray area below the threshold dotted line (&lt;0.57 but ≥0.45 for MIA PaCa-2 cells and &lt;0.74 but ≥0.51 for AsPC-1 cells) were potentially functionally neutral. For raw data in this figure, please refer to <xref ref-type="supplementary-material" rid="fig3s2sdata1">Figure 3—figure supplement 2—source data 1</xref>.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Raw data in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-fig3-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Functional characterization of <italic>CDKN2A</italic> variants.</title><p>Functional characterization of 45 <italic>CDKN2A</italic> variants (9 pathogenic variants, 7 benign variants, 29 variants of uncertain significance [VUSs]). Cell proliferation values are shown as mean of PANC-1, MIA PaCa-2, and AsPc-1 cell values. Assayed variants with mean cell proliferation values: (1) above the gray shaded area (&gt;0.83) were classified as functionally deleterious, (2) below the gray shaded area (&lt;0.47) were classified as functionally benign, (3) in the gray area above the threshold dotted line (≥0.62 but ≤0.83) were potentially functionally deleterious, and (4) in the gray area below the threshold dotted line (&lt;0.62 but ≥0.47) were potentially functionally neutral. For raw data in this figure, please refer to <xref ref-type="supplementary-material" rid="fig3s3sdata1">Figure 3—figure supplement 3—source data 1</xref>.</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3—figure supplement 3—source data 1.</label><caption><title>Raw data in <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-fig3-figsupp3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig3-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Functional characterization and reclassification of <italic>CDKN2A</italic> VUS</title><p>We used our cell proliferation assay to functionally characterize and reclassify 29 germline <italic>CDKN2A</italic> VUSs. These VUSs were selected because they were either reported in previously published studies in patients with PDAC and/or were reported in ClinVar (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Eleven of the 29 VUSs (37.9%) had cell proliferation scores above 0.81 and were classified as functionally deleterious, including p.Thr18Pro, p.Ala20Gly, p.Gln50Arg, p.His66Pro, p.Ala68Val, p.Asp74Ala,, p.Asp84Ala, p.Gly89Asp, p.Ala109Pro, p.Ala127Pro, and p.Arg128Pro. One VUS (3.4%), p.Leu65Pro, had a cell proliferation score between 0.66 and 0.81 and was classified as potentially functionally deleterious. Three VUSs (10.3%), p.Asp74His, p.Gly111Ser, and, p.Gly122Val, had a cell proliferation score between 0.66 and 0.44 and were classified as potentially functionally neutral. The remaining 14 VUSs (48.3%) had cell proliferation scores below 0.44 and were classified as functionally neutral, including p.Met9Thr, p.Pro11Leu, p.Arg24Gln, p.Pro41Gln, p.His66Arg, p.Gly67Arg, p.Glu69Gly, p.Arg99Gly, p.Gly101Arg, p.Arg124Cys, p.Asp125His, p.Ala134Thr, p.Gly139Arg, p.Ala143Thr. Taken together, 12 of the 29 germline <italic>CDKN2A</italic> variants previously classified as VUSs, representing over 40% of assayed VUSs, demonstrated aberrant function in our assay and would be reclassified as likely pathogenic based on ACMG guidelines that consider validated in vitro functional assays showing a deleterious effect for a variant as strong evidence to support pathogenicity (<xref ref-type="bibr" rid="bib22">Richards et al., 2015</xref>).</p></sec><sec id="s2-4"><title>Assay of CDKN2A VUSs in additional PDAC cell lines</title><p>To determine if the PDAC cell line used in our assay affected variant functional characterizations, we assayed all <italic>CDKN2A</italic> variants (benchmark pathogenic, benchmark benign, and VUS) using two additional PDAC cell lines with homozygous deletions of <italic>CDKN2A</italic>: MIA PaCa-2 (ATCC, catalog no. CRL-1420) and AsPC-1 (ATCC, catalog no. CRL-1682) (<xref ref-type="bibr" rid="bib34">Yamato and Furukawa, 2001</xref>). Western blot for CDKN2A did not detect expression of p16<sup>INK4A</sup> in either cell line (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Importantly, there was clear demarcation between the mean cell proliferation values of assayed benchmark pathogenic and benign variants in both MIA PaCa-2 and AsPC-1 (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A-B</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In MIA PaCa-2 cells, 7 (24.1%) VUSs were characterized as functionally deleterious, 5 (17.2%) as potentially functionally deleterious, 3 (10.3%) as potentially functionally neutral, and 14 (48.3%) as functionally neutral based on their mean cell proliferation values (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In AsPC-1 cells, 6 (20.7%) VUSs were characterized as functionally deleterious, 6 (20.7%) as potentially functionally deleterious, 8 (27.6%) as potentially functionally neutral, and 9 (31%) as functionally neutral based on their mean cell proliferation values (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Importantly, there was classification agreement between VUS functional classifications across cell lines (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). When considering mean cell proliferation values for variants across all cell lines, 11 VUSs (20.7%; p.Thr18Pro, p.Gln50Arg, p.Leu65Pro, p.His66Pro, p.Ala68Val, p.Asp74Ala, p.Asp84Ala, p.Gly89Asp, p.Ala109Pro, p.Ala127Pro, and p.Arg128Pro) were classified as functionally deleterious, 1 VUS (3.4%; p.Ala20Gly) was potentially functionally deleterious, 2 VUSs (6.9%; p.Asp74His and p.Gly122Val) were potentially functionally neutral, and 15 VUSs (51.7%; p.Met9Thr, p.Pro11Leu, p.Arg24Gln, p.Pro41Gln, p.His66Arg, p.Gly67Arg, p.Glu69Gly, p.Arg99Gly, p.Gly101Arg, p.Gly111Ser, p.Arg124Cys, p.Asp125His, p.Ala134Thr, p.Gly139Arg, and p.Ala143Thr) were functionally neutral (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p></sec><sec id="s2-5"><title>Analysis of cell cycle progression</title><p>As reintroduction of CDKN2A into cancer cells lacking CDKN2A delays cell cycle progression, we determined the percent of variant-expressing PANC-1 cells in G1, G2/M, and S phases of the cell cycle (<xref ref-type="bibr" rid="bib20">Miller et al., 2011</xref>). The percent of cells in G1 phase for benchmark pathogenic variants (47.2%, range: 43–50.9%) and VUSs with functionally deleterious or potentially functionally deleterious classifications (48.5%, range: 42.2–52.3%) were significantly lower than benchmark benign variants (63.1%, range: 58.4–67.1%) (p-value &lt; 0.01, Student’s t test) and VUSs with functionally neutral or potentially functionally neutral classifications (62.8%, range: 57.6–68.8%) (p-value &lt; 0.01, Student’s t test) (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s4">4</xref>). Similarly, the percent of cells in G2/M phase for benchmark pathogenic variants (42.4%, range: 37.7–49.2%) and VUSs with functionally deleterious or potentially functionally deleterious classifications (40.4%, range: 37.3–45.5%) were significantly lower than benchmark benign variants (25.7%, range: 19.3–35.1%) and VUSs with functionally neutral or potentially functionally neutral classifications (26.6%, range: 18.9–36.6%) (p-value &lt; 0.01, Student’s t test) (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>). These data are consistent with the functional classifications from our cell proliferation assay.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Cell cycle analysis of <italic>CDKN2A</italic> variants.</title><p>G1 percent for 45 <italic>CDKN2A</italic> variants (9 pathogenic variants, 7 benign variants, 29 variants of uncertain significance [VUSs]) in PANC-1 cells. Significant inhibition of G1 arrest function of CDKN2A by benchmark pathogenic variants and functionally deleterious or potentially functionally deleterious VUSs. *p &lt; 0.01. For raw data in this figure, please refer to <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="table" rid="table1">Table 1</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw data in <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Cell cycle analysis of benchmark pathogenic <italic>CDKN2A</italic> variants.</title><p>Cell cycle analysis was performed with percentages of cells in each phase (G1, G2_M, and S) indicated. Flow cytometry analysis images for PANC-1 cell stably expressed with empty vector or benchmark pathogenic variants.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Cell cycle analysis of benchmark benign <italic>CDKN2A</italic> variants.</title><p>Cell cycle analysis was performed with percentages of cells in each phase (G1, G2_M, and S) indicated. Flow cytometry analysis images for PANC-1 cell stably expressed with empty vector or benchmark benign variants.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Cell cycle analysis of functionally deleterious and potentially functionally deleterious <italic>CDKN2A</italic> variants of uncertain significance (VUSs).</title><p>Cell cycle analysis was performed with percentages of cells in each phase (G1, G2_M, and S) indicated. Flow cytometry analysis images for PANC-1 cell stably expressed with empty vector or functionally deleterious and potentially functionally deleterious VUSs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Cell cycle analysis of functionally neutral and potentially functionally neutral <italic>CDKN2A</italic> variants of uncertain significance (VUSs).</title><p>Cell cycle analysis was performed with percentages of cells in each phase (G1, G2_M, and S) indicated. Flow cytometry analysis images for PANC-1 cell stably expressed with empty vector or functionally neutral and potentially functionally neutral VUSs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>G2_M percent of <italic>CDKN2A</italic> variants expression cells.</title><p>G2_M percent for 45 <italic>CDKN2A</italic> variants (9 pathogenic variants, 7 benign variants, 29 variants of uncertain significance [VUS]) in PANC-1 cells. G2_M percent in benchmark pathogenic variants and functionally deleterious or potentially functionally deleterious VUSs expression cells were significantly higher than that in benchmark benign variants expression cells. *p &lt; 0.01. For raw data in this figure, please refer to <xref ref-type="fig" rid="fig4">Figure 4</xref> and 1.</p><p><supplementary-material id="fig4s5sdata1"><label>Figure 4—figure supplement 5—source data 1.</label><caption><title>Raw data in <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-fig4-figsupp5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71137-fig4-figsupp5-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Comparison with previously reported functional data</title><p>Five of the 29 <italic>CDKN2A</italic> VUSs assayed had previously reported functional data available (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). In agreement with our functional classification, p.Arg24Gln and p.Gly101Arg did not demonstrate deleterious effects in previously reported CDK4 binding and cell proliferation assays (<xref ref-type="bibr" rid="bib12">Jenkins et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Kannengiesser et al., 2009</xref>; <xref ref-type="bibr" rid="bib20">Miller et al., 2011</xref>). p.Gly122Val previously demonstrated CDK6 binding similar to WT CDKN2A, binding to CDK4 was significantly reduced, and partially inhibit cell proliferation (<xref ref-type="bibr" rid="bib33">Yakobson et al., 2000</xref>). In our study, p.Gly122Val partially inhibited cell proliferation and clustered with potentially functionally neutral variants. Furthermore, p.Gly67Arg and p.Glu69Gly were previously shown to result in a 40% reduction in CDK4 binding compared to WT CDKN2A (<xref ref-type="bibr" rid="bib13">Kannengiesser et al., 2009</xref>). In our study, p.Gly67Arg and p.Glu69Gly clearly inhibited cell proliferation and clustered with functionally neutral variants.</p></sec><sec id="s2-7"><title>Prevalence of functionally deleterious <italic>CDKN2A</italic> VUS in patients with PDAC</title><p>As the assayed <italic>CDKN2A</italic> VUSs included variants identified in previously published studies of patients with PDAC, we next determined the prevalence of functionally deleterious VUSs, VUSs that could be reclassified as likely pathogenic variants, in separate cohorts of patients with PDAC. Ten (58.8%) of the 17 <italic>CDKN2A</italic> VUSs identified in a study of 638 patients with familial pancreatic cancer (<xref ref-type="bibr" rid="bib23">Roberts et al., 2016</xref>) were found to be functionally deleterious in our assay and could be reclassified as likely pathogenic variants. In another study of 727 patients with a family history of PDAC, including patients that did not meet the criteria for classification as familial pancreatic cancer, 6 (46.2%) of 13 <italic>CDKN2A</italic> VUSs identified were functionally deleterious in our assay (<xref ref-type="bibr" rid="bib35">Zhen et al., 2015</xref>). Similarly, in a study of 302 patients with a family history of PDAC, 4 of the 9 (44.4%) <italic>CDKN2A</italic> VUSs reported were functionally deleterious in our assay (<xref ref-type="bibr" rid="bib6">Chaffee et al., 2018</xref>). Combining these latter two study results, there were 10 functionally deleterious <italic>CDKN2A</italic> variants that could be reclassified as likely pathogenic variants in 1029 patients with a family history of PDAC.</p><p>When considering patients with PDAC unselected for family history, in one study of 350 patients with PDAC (<xref ref-type="bibr" rid="bib19">McWilliams et al., 2018</xref>), 3 of 8 (37.5%) VUSs identified were classified as functionally deleterious in our assay. On the other hand, in another study of 854 patients with PDAC unselected for family history, the one VUS identified was found to be functionally neutral (<xref ref-type="bibr" rid="bib25">Shindo et al., 2017</xref>). Similarly, when combining these data, three functionally deleterious <italic>CDKN2A</italic> variants that could be reclassified as likely pathogenic variants were identified in 1204 patients with PDAC unselected for family history.</p><p>As we assayed all <italic>CDKN2A</italic> VUSs reported in these studies, our data indicate that the prevalence of likely pathogenic germline <italic>CDKN2A</italic> variants initially characterized as VUSs is 1.6% (95% CI: 0.8–2.9%) in patients with familial pancreatic cancer, 0.9% (95% CI: 0.5–1.8%) in patients with PDAC positive family history of PDAC (including patients that did not meet the criteria for classification as familial pancreatic cancer), and 0.1% (95% CI: 0.02–0.3%) in PDAC patients unselected for family history. When incorporating functionally deleterious VUSs we have reclassified as likely pathogenic variants with known pathogenic variants in <italic>CDKN2A</italic>, the cumulative prevalence of pathogenic and likely pathogenic <italic>CDKN2A</italic> variants in these studies increased from 2.5% to 4.1% (95% CI: 2.8–5.9%) in patients with familial pancreatic cancer, from 1.7% to 2.7% (95% CI: 1.9–3.9%) in patients with PDAC who had a positive for a family history of the disease (including patients that did not meet the criteria for classification as familial pancreatic cancer), and from 0.7% to 1.0% (95% CI: 0.6–1.7%) in PDAC patients unselected for family history.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Germline <italic>CDKN2A</italic> VUSs are identified in up to 4.3% patients with PDAC and are the cause of significant clinical uncertainty. Individuals with a <italic>CDKN2A</italic> VUS are not currently eligible for surveillance unless they meet other family history criteria. We used a cell proliferation assay to functionally characterize germline <italic>CDKN2A</italic> VUSs identified in patients with PDAC and/or reported in ClinVar and provide evidence to reclassify variants into clinically actionable strata.</p><p>We found that over 40% of <italic>CDKN2A</italic> variants previously classified as VUS were functionally deleterious in our assay and could be reclassified as likely pathogenic variants (12 of 29 <italic>CDKN2A</italic> VUSs; 41.4%). When considering <italic>CDKN2A</italic> VUS identified in patients with PDAC, our results suggest that the prevalence of <italic>CDKN2A</italic> VUSs that are functionally deleterious is up to 1.6% in patients with PDAC, depending on family history. It should be noted, however, that we characterized only missense <italic>CDKN2A</italic> VUS in our assay. Functional characterization of other types of <italic>CDKN2A</italic> VUS, such as synonymous variants, in-frame indels, and non-coding variants, would refine these estimates.</p><p>Furthermore, we determined the prevalence of germline <italic>CDKN2A</italic> VUSs that are functionally deleterious in patients with PDAC reported in previously published literature. Overlap of patient cohorts between these studies may affect estimates of prevalence. Regardless, we can conclude that functionally deleterious <italic>CDKN2A</italic> VUSs are likely to play a significant and previously unappreciated role in risk of PDAC, particularly for patients with a family history of the disease. Studies to define age-specific penetrance estimates for individuals with a pathogenic germline <italic>CDKN2A</italic> variant, including functionally deleterious variants previously classified as VUSs, are necessary and will inform genetic counselling, surveillance, and early detection efforts.</p><p>VUS functional characterizations were generally consistent when using PANC-1, MIA PaCA-2, and AsPC-1 cells in our cell proliferation assay. Specifically, no variant found to be functionally deleterious or potentially functionally deleterious when assayed with one cell line, had a functionally neutral or potentially functionally neutral classification when assayed with another cell line. Furthermore, PDAC cell lines had different genetic alterations and degrees of ploidy (<xref ref-type="bibr" rid="bib28">Sirivatanauksorn et al., 2001</xref>; <xref ref-type="bibr" rid="bib34">Yamato and Furukawa, 2001</xref>) indicating that our functional classifications are robust to cell line-specific effects.</p><p>Consistent with our functional classifications, we found that benchmark pathogenic variants and VUSs classified as functionally deleterious or potentially functionally deleterious had a significantly lower percent of cells in G1 phase and a significantly higher percent of cells in G2/M phase of the cell cycle compared to either benchmark benign variants or VUSs classified as functionally benign or potentially functionally benign. These data suggest that expression of <italic>CDKN2A</italic> variants classified as pathogenic, functionally deleterious, or potentially functionally deleterious do not control progression through the cell cycle.</p><p>We were also able to compare our assay results for five <italic>CDKN2A</italic> VUSs with previously published data. In general, our assay results were consistent with previous reports. However, assay results for two VUSs, p.Gly67Arg and p.Glu69Gly, were inconsistent with previously reported partial reduction in CDK4 binding. There are several explanations for these observations. First, our assay is of broad cellular function, specifically cell proliferation, and therefore, may encompass functions other than CDK4 binding. Second, it is possible that overexpression of <italic>CDKN2A</italic> variants with partial loss-of-function may be obscured in our assay by non-physiological levels of expression. Future studies to correlate CDK4 binding with pathogenicity and to develop of functional assays that utilize endogenous promoters and enhancers would provide further clarity.</p><p>In conclusion, we functionally characterized and reclassified 29 <italic>CDKN2A</italic> VUSs identified in patients with PDAC or reported in ClinVar using a validated functional assay. We found that over 40% of <italic>CDKN2A</italic> VUS assayed were, in fact, functionally deleterious and as a result can be reclassified as likely pathogenic using ACMG guidelines. This finding may have significant implications for the management of patients with PDAC, and their relatives found to have a <italic>CDKN2A</italic> VUS.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell lines</title><p>PANC-1 (catalog no. CRL-1469), MIA PaCa-2 (catalog no. CRL-1420), and AsPC-1 (catalog no. CRL-1682), and the human embryonic kidney cell line 293T (catalog no. CRL-3216) were purchased from American Type Culture Collection (Manassas, VA). PANC-1, MIA PaCa-2, and 293T cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. AsPC-1 cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum. Cell line authentication and mycoplasma testing of PDAC cell lines was performed using GenePrint 10 System (Promega Corporation, Madison, WI; catalog no. B9510) and a PCR-based MycoDtect kit (Greiner Bio-One, Monroe, NC; catalog no. 463 060), respectively, by the Genetics Resource Core Facility of The Johns Hopkins University School of Medicine, Baltimore, MD.</p></sec><sec id="s4-2"><title>Western blot</title><p>Western blots were performed as previously described with the following modifications (<xref ref-type="bibr" rid="bib31">Tamura, 2018</xref>): (1) anti-vinculin primary antibody was used at a 1:5000 dilution (Cell Signaling Technology, Beverly, MA; catalog no. 13901), (2) anti-CDKN2A primary antibody was used to detect p16<sup>INK4A</sup> at a 1:1000 dilution (Cell Signaling Technology, Beverly, MA; catalog no. 92803). Western blotting data and images presented are representative of at least three independent experiments.</p></sec><sec id="s4-3"><title>Plasmid construction</title><p>pHAGE-CDKN2A (Addgene, plasmid no. 116726) and pHAGE-CDKN2A-L78Hfs*41 (Addgene, plasmid no. 116222) created by Gordon Mills &amp; Kenneth Scott (<xref ref-type="bibr" rid="bib21">Ng et al., 2018</xref>), and pLJM1-Empty (Addgene, plasmid no. 91980) created by Joshua Mendell (<xref ref-type="bibr" rid="bib9">Golden et al., 2017</xref>) were obtained from Addgene (Watertown, MA). <italic>CDKN2A</italic> and <italic>CDKN2A</italic>-L78Hfs*41 cDNAs were subcloned into the pLJM1-Empty from pHAGE-CDKN2A and pHAGE-CDKN2A-L78Hfs*41, respectively, using the Q5 High-Fidelity PCR kit (New England Biolabs, Ipswich, MA; catalog no. E0555S) as previously described (<xref ref-type="bibr" rid="bib36">Zhen et al., 2017</xref>). Primers used to subclone <italic>CDKN2A</italic> and <italic>CDKN2A</italic>-L78Hfs*41 cDNAs are given in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>. Integration of <italic>CDKN2A</italic> cDNA was confirmed by restriction enzyme digest using EcoRI-HF (New England Biolabs, Ipswich, MA; catalog no. R3101S) and Sanger sequencing (Genewiz, Plainsfield, NJ). Restriction enzyme, EcoRI-HF digest was performed with CutSmart Buffer (New England Biolabs, Ipswich, MA; catalog no. B7204S) at 37°C for 15 min. Expression constructs for each assayed <italic>CDKN2A</italic> variant were produced from the pLJM1-CDKN2A using the Q5 Site-Directed Mutagenesis kit (New England Biolabs, Ipswich, MA; catalog no. E0552). Primers used to generate each <italic>CDKN2A</italic> variant expression plasmids are given in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>. Integration of each <italic>CDKN2A</italic> VUS was confirmed using Sanger sequencing (Genewiz, Plainsfield, NJ). The manufacturer’s protocol was followed unless otherwise specified.</p></sec><sec id="s4-4"><title>Lentivirus production and generation of CDKN2A expressing PANC-1 cells</title><p>pLJM1 lentiviral expression vectors harboring a <italic>CDKN2A</italic> cDNA (WT or variant) and the lentiviral packaging vectors, psPAX2 (Addgene, plasmid no. 12260) and pCMV-VSV-G (Addgene, plasmid no. 8454), created by Didier Trono and Bob Weinberg, respectively (<xref ref-type="bibr" rid="bib29">Stewart et al., 2003</xref>), were transfected into 293T cells using Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, Waltham, MA; catalog no. L3000008). Media was collected at 24 and 48 hr and lentiviral particles were concentrated with Lenti-X Concentrator (Clontech, Mountain View, CA; catalog no. 631231). Manufacturer’s protocols were used unless otherwise specified.</p><p>PANC-1, MIA PaCa-2, and AsPC-1 cells stably expressing WT CDKN2A (p16<sup>INK4A</sup>) or selected variants were generated by lentiviral transduction. Briefly, 1 × 10<sup>5</sup> cells were cultured in media supplemented with 10 µg/ml polybrene and transduced with 10 TUs/ml lentivirus particles. Cells were then centrifuged at 1200× <italic>g</italic> for 1 hr. After 48 hr of culture at 37°C and 5% CO<sub>2</sub>, transduced cells were selected by culture in media containing 3 µg/ml puromycin for PANC-1 cells and 1 µg/ml puromycin for MIA PaCa-2 and AsPC-1 cells for 7 days.</p></sec><sec id="s4-5"><title>Cell proliferation assay and functional characterization</title><p>1 × 10<sup>5</sup> PANC-1, MIA PaCa-2, and AsPC-1 cells were seeded into culture (day 0) and cell numbers were counted using a TC20 Automated Cell Counter (Bio-Rad Laboratories, Hercules, CA, catalog no. 1450102) on day 7 for MIAPaCa-2 cells, and day 14 for PANC-1 and AsPC-1 cells. Cell numbers were normalized to empty vector transduced cells to give a relative cell proliferation value. Assays to determine the functional effect of <italic>CDKN2A</italic> variants were repeated in triplicate. Mean cell proliferation value and standard deviation (s.d.) were calculated.</p><p><italic>CDKN2A</italic> VUSs were functionally characterized into four categories: (1) deleterious, (2) potentially deleterious, (3) potentially neutral, and (4) neutral, based on the results of the cell proliferation assay using previously described methodology (<xref ref-type="bibr" rid="bib1">Bouvet et al., 2019</xref>). Briefly, functionally deleterious was defined as cell proliferation values greater than the Z-score 95% CI upper limit calculated from benchmark pathogenic variants and benign variants. Functionally neutral was defined as proliferation values less than the Z-score 95% CI lower limit. Assayed variants with cell proliferation values between the thresholds for functionally deleterious and functionally neutral were characterized as potentially functionally deleterious or potentially functionally neutral if they had proliferation values above or below a cutoff determined by the ROC curve and Youden index.</p></sec><sec id="s4-6"><title>Cell cycle analysis</title><p>PANC-1 cells were incubated with 10 nM EdU for 2 hr, then harvested by trypsinization, washed, fixed, and stained using the Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit (Invitrogen, Carlsbad, CA, catalog no. C10425) and the FxCycle Violet Ready Flow Reagent (Invitrogen, catalog no. R37166) according to the manufacturer’s protocols. Flow cytometry was performed on Cytek Aurora Flow Cytometry System (Cytek Biosciences, Fremont, CA) and the data analyzed to determine the percentage of cells in each phase of the cell cycle using the FlowJo software (BD Biosciences, San Jose, CA).</p></sec><sec id="s4-7"><title>Statistical analyses</title><p>Statistical analyses were performed using JMP v.11 (SAS, Cary, NC) and Prism v.6 (GraphPad, San Diego, CA). Comparison of means used the Student’s t test. CIs for the prevalence of functionally deleterious <italic>CDKN2A</italic> variants were calculated using the modified Wald Method. A p-value less than 0.05 considered statistically significant.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>RHH has the right to receive royalty payments from Thrive Earlier Diagnosis for the GNAS in pancreatic cysts invention in a relationship overseen by Johns Hopkins University</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Validation</p></fn><fn fn-type="con" id="con4"><p>Investigation, Resources, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-71137-transrepform1-v2.docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>CDKN2A variants assayed with genomic, transcript, and protein change.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Functional characterization.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Previously reported functional data for assayed CDKN2A variants.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Primer sequences used for subconing and site directed mutagenesis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-71137-supp4-v2.xlsx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript, supporting files, and as Source data and Source code.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors would like to thank to Dr Xiaoling Zhang at The Johns Hopkins University School of Medicine Ross Flow Cytometry Core Facility for technical assistance. Data used in this article were obtained from the Familial Pancreatic Cancer Genome Sequencing Project (FPC-GSP; <ext-link ext-link-type="uri" xlink:href="https://www.familialpancreaticcancer.org">https://www.familialpancreaticcancer.org</ext-link>). The FPC-GSP investigators contributed to the design and implementation of FPC-GSP and/or provided data. They did not participate in analysis or writing of this report. The FPC-GSP project was generously supported by Dennis Troper and Susan Wojcicki, the Lustgarten Foundation for Pancreatic Cancer Research, the Sol Goldman Pancreatic Cancer Research Center, the Virginia and DK Ludwig Fund for Cancer Research, the Michael Rolfe Foundation, the Joseph C Monastra Foundation, the Gerald O Mann Charitable Foundation, the Ladies Auxiliary to the Veterans of Foreign Wars, the friends and family of Roger L Kerns Sr, the Weston Garfield Foundation, the NIH Specialized Programs of Research Excellence P30CA006973 and P50CA102701, and NIH grants K99-CA190889, R01-CA57345, R01-CA97075, R01-CA154823, and R01-DK060694.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvet</surname><given-names>D</given-names></name><name><surname>Bodo</surname><given-names>S</given-names></name><name><surname>Munier</surname><given-names>A</given-names></name><name><surname>Guillerm</surname><given-names>E</given-names></name><name><surname>Bertrand</surname><given-names>R</given-names></name><name><surname>Colas</surname><given-names>C</given-names></name><name><surname>Duval</surname><given-names>A</given-names></name><name><surname>Coulet</surname><given-names>F</given-names></name><name><surname>Muleris</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome</article-title><source>Gastroenterology</source><volume>157</volume><fpage>421</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.03.071</pub-id><pub-id pub-id-type="pmid">30998989</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Borazanci</surname><given-names>E</given-names></name><name><surname>Speare</surname><given-names>V</given-names></name><name><surname>Dudley</surname><given-names>B</given-names></name><name><surname>Karloski</surname><given-names>E</given-names></name><name><surname>Peters</surname><given-names>MLB</given-names></name><name><surname>Stobie</surname><given-names>L</given-names></name><name><surname>Bahary</surname><given-names>N</given-names></name><name><surname>Zeh</surname><given-names>H</given-names></name><name><surname>Zureikat</surname><given-names>A</given-names></name><name><surname>Hogg</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Tsung</surname><given-names>A</given-names></name><name><surname>Rhee</surname><given-names>J</given-names></name><name><surname>Ohr</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Moser</surname><given-names>AJ</given-names></name><name><surname>DeLeonardis</surname><given-names>K</given-names></name><name><surname>Krejdovsky</surname><given-names>J</given-names></name><name><surname>Dalton</surname><given-names>E</given-names></name><name><surname>LaDuca</surname><given-names>H</given-names></name><name><surname>Dolinsky</surname><given-names>J</given-names></name><name><surname>Colvin</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Black</surname><given-names>MH</given-names></name><name><surname>Tung</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma</article-title><source>Cancer</source><volume>124</volume><fpage>3520</fpage><lpage>3527</lpage><pub-id pub-id-type="doi">10.1002/cncr.31628</pub-id><pub-id pub-id-type="pmid">30067863</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Hahn</surname><given-names>SA</given-names></name><name><surname>da Costa</surname><given-names>LT</given-names></name><name><surname>Redston</surname><given-names>MS</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Seymour</surname><given-names>AB</given-names></name><name><surname>Weinstein</surname><given-names>CL</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Yeo</surname><given-names>CJ</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma</article-title><source>Nature Genetics</source><volume>8</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/ng0994-27</pub-id><pub-id pub-id-type="pmid">7726912</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canto</surname><given-names>MI</given-names></name><name><surname>Harinck</surname><given-names>F</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Offerhaus</surname><given-names>GJ</given-names></name><name><surname>Poley</surname><given-names>JW</given-names></name><name><surname>Kamel</surname><given-names>I</given-names></name><name><surname>Nio</surname><given-names>Y</given-names></name><name><surname>Schulick</surname><given-names>RS</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Kluijt</surname><given-names>I</given-names></name><name><surname>Levy</surname><given-names>MJ</given-names></name><name><surname>Chak</surname><given-names>A</given-names></name><name><surname>Fockens</surname><given-names>P</given-names></name><name><surname>Goggins</surname><given-names>M</given-names></name><name><surname>Bruno</surname><given-names>M</given-names></name><collab>International Cancer of Pancreas Screening CAPS Consortium</collab></person-group><year iso-8601-date="2013">2013</year><article-title>International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer</article-title><source>Gut</source><volume>62</volume><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2012-303108</pub-id><pub-id pub-id-type="pmid">23135763</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canto</surname><given-names>M.I</given-names></name><name><surname>Almario</surname><given-names>JA</given-names></name><name><surname>Schulick</surname><given-names>RD</given-names></name><name><surname>Yeo</surname><given-names>CJ</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Blackford</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>EJ</given-names></name><name><surname>Sanyal</surname><given-names>A</given-names></name><name><surname>Yenokyan</surname><given-names>G</given-names></name><name><surname>Lennon</surname><given-names>AM</given-names></name><name><surname>Kamel</surname><given-names>IR</given-names></name><name><surname>Fishman</surname><given-names>EK</given-names></name><name><surname>Wolfgang</surname><given-names>C</given-names></name><name><surname>Weiss</surname><given-names>M</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Goggins</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance</article-title><source>Gastroenterology</source><volume>155</volume><fpage>740</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.05.035</pub-id><pub-id pub-id-type="pmid">29803839</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaffee</surname><given-names>KG</given-names></name><name><surname>Oberg</surname><given-names>AL</given-names></name><name><surname>McWilliams</surname><given-names>RR</given-names></name><name><surname>Majithia</surname><given-names>N</given-names></name><name><surname>Allen</surname><given-names>BA</given-names></name><name><surname>Kidd</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Hartman</surname><given-names>AR</given-names></name><name><surname>Wenstrup</surname><given-names>RJ</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prevalence of Germline Mutations in Cancer Genes</article-title><source>Genetics in Medicine</source><volume>20</volume><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1038/gim.2017.85.PREVALENCE</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MT</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>SP</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Chapman</surname><given-names>JS</given-names></name><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>JJ</given-names></name><name><surname>Socci</surname><given-names>ND</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Olshen</surname><given-names>AB</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1038/nbt.3391</pub-id><pub-id pub-id-type="pmid">26619011</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goggins</surname><given-names>M</given-names></name><name><surname>Overbeek</surname><given-names>KA</given-names></name><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Syngal</surname><given-names>S</given-names></name><name><surname>Del Chiaro</surname><given-names>M</given-names></name><name><surname>Bartsch</surname><given-names>DK</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Carrato</surname><given-names>A</given-names></name><name><surname>Farrell</surname><given-names>J</given-names></name><name><surname>Fishman</surname><given-names>EK</given-names></name><name><surname>Fockens</surname><given-names>P</given-names></name><name><surname>Gress</surname><given-names>TM</given-names></name><name><surname>van Hooft</surname><given-names>JE</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Kastrinos</surname><given-names>F</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Lennon</surname><given-names>AM</given-names></name><name><surname>Lucas</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>W</given-names></name><name><surname>Rustgi</surname><given-names>A</given-names></name><name><surname>Simeone</surname><given-names>D</given-names></name><name><surname>Stoffel</surname><given-names>E</given-names></name><name><surname>Vasen</surname><given-names>HFA</given-names></name><name><surname>Cahen</surname><given-names>DL</given-names></name><name><surname>Canto</surname><given-names>MI</given-names></name><name><surname>Bruno</surname><given-names>M</given-names></name><collab>International Cancer of the Pancreas Screening (CAPS) consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium</article-title><source>Gut</source><volume>69</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-319352</pub-id><pub-id pub-id-type="pmid">31672839</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Manjunath</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>V</given-names></name><name><surname>Chang</surname><given-names>TC</given-names></name><name><surname>Kopp</surname><given-names>F</given-names></name><name><surname>Ramirez-Martinez</surname><given-names>A</given-names></name><name><surname>Tagliabracci</surname><given-names>VS</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Mendell</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An Argonaute phosphorylation cycle promotes microRNA-mediated silencing</article-title><source>Nature</source><volume>542</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1038/nature21025</pub-id><pub-id pub-id-type="pmid">28114302</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>IP</given-names></name><name><surname>Marks</surname><given-names>DL</given-names></name><name><surname>Koenig</surname><given-names>AN</given-names></name><name><surname>Hogenson</surname><given-names>TL</given-names></name><name><surname>Almada</surname><given-names>LL</given-names></name><name><surname>Goldstein</surname><given-names>LE</given-names></name><name><surname>Romecin Duran</surname><given-names>PA</given-names></name><name><surname>Vera</surname><given-names>R</given-names></name><name><surname>Vrabel</surname><given-names>AM</given-names></name><name><surname>Cui</surname><given-names>G</given-names></name><name><surname>Rabe</surname><given-names>KG</given-names></name><name><surname>Bamlet</surname><given-names>WR</given-names></name><name><surname>Mer</surname><given-names>G</given-names></name><name><surname>Sicotte</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><name><surname>Fernandez-Zapico</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A rare germline CDKN2A variant (47T&gt;G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition</article-title><source>The Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100634</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100634</pub-id><pub-id pub-id-type="pmid">33823155</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Hart</surname><given-names>SN</given-names></name><name><surname>Polley</surname><given-names>EC</given-names></name><name><surname>Gnanaolivu</surname><given-names>R</given-names></name><name><surname>Shimelis</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Lilyquist</surname><given-names>J</given-names></name><name><surname>Na</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Antwi</surname><given-names>SO</given-names></name><name><surname>Bamlet</surname><given-names>WR</given-names></name><name><surname>Chaffee</surname><given-names>KG</given-names></name><name><surname>DiCarlo</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Samara</surname><given-names>R</given-names></name><name><surname>Kasi</surname><given-names>PM</given-names></name><name><surname>McWilliams</surname><given-names>RR</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer</article-title><source>JAMA</source><volume>319</volume><fpage>2401</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.6228</pub-id><pub-id pub-id-type="pmid">29922827</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>NC</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Wilde</surname><given-names>M</given-names></name><name><surname>Holmen</surname><given-names>SL</given-names></name><name><surname>Grossman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions</article-title><source>The Journal of Investigative Dermatology</source><volume>133</volume><fpage>1043</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.401</pub-id><pub-id pub-id-type="pmid">23190892</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kannengiesser</surname><given-names>C</given-names></name><name><surname>Brookes</surname><given-names>S</given-names></name><name><surname>del Arroyo</surname><given-names>AG</given-names></name><name><surname>Pham</surname><given-names>D</given-names></name><name><surname>Bombled</surname><given-names>J</given-names></name><name><surname>Barrois</surname><given-names>M</given-names></name><name><surname>Mauffret</surname><given-names>O</given-names></name><name><surname>Avril</surname><given-names>M-FM</given-names></name><name><surname>Chompret</surname><given-names>A</given-names></name><name><surname>Lenoir</surname><given-names>GM</given-names></name><name><surname>Sarasin</surname><given-names>A</given-names></name><collab>French Hereditary Melanoma Study Group</collab><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Bressac-de Paillerets</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients</article-title><source>Human Mutation</source><volume>30</volume><fpage>564</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1002/humu.20845</pub-id><pub-id pub-id-type="pmid">19260062</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>B</given-names></name><name><surname>Shapira-Frommer</surname><given-names>R</given-names></name><name><surname>Schmutzler</surname><given-names>RK</given-names></name><name><surname>Audeh</surname><given-names>MW</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name><name><surname>Balmaña</surname><given-names>J</given-names></name><name><surname>Mitchell</surname><given-names>G</given-names></name><name><surname>Fried</surname><given-names>G</given-names></name><name><surname>Stemmer</surname><given-names>SM</given-names></name><name><surname>Hubert</surname><given-names>A</given-names></name><name><surname>Rosengarten</surname><given-names>O</given-names></name><name><surname>Steiner</surname><given-names>M</given-names></name><name><surname>Loman</surname><given-names>N</given-names></name><name><surname>Bowen</surname><given-names>K</given-names></name><name><surname>Fielding</surname><given-names>A</given-names></name><name><surname>Domchek</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><fpage>244</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.56.2728</pub-id><pub-id pub-id-type="pmid">25366685</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>AP</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Roberts</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer</article-title><source>Pancreas</source><volume>50</volume><fpage>1123</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000001888</pub-id><pub-id pub-id-type="pmid">34714275</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Uram</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Kemberling</surname><given-names>H</given-names></name><name><surname>Eyring</surname><given-names>AD</given-names></name><name><surname>Skora</surname><given-names>AD</given-names></name><name><surname>Luber</surname><given-names>BS</given-names></name><name><surname>Azad</surname><given-names>NS</given-names></name><name><surname>Laheru</surname><given-names>D</given-names></name><name><surname>Biedrzycki</surname><given-names>B</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name><name><surname>Zaheer</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>GA</given-names></name><name><surname>Crocenzi</surname><given-names>TS</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>de la Chapelle</surname><given-names>A</given-names></name><name><surname>Koshiji</surname><given-names>M</given-names></name><name><surname>Bhaijee</surname><given-names>F</given-names></name><name><surname>Huebner</surname><given-names>T</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Cuka</surname><given-names>N</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Cornish</surname><given-names>TC</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PD-1 Blockade in Tumors with Mismatch-Repair Deficiency</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>2509</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmid">26028255</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowery</surname><given-names>MA</given-names></name><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>Jordan</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Kemel</surname><given-names>Y</given-names></name><name><surname>Vijai</surname><given-names>J</given-names></name><name><surname>Mandelker</surname><given-names>D</given-names></name><name><surname>Zehir</surname><given-names>A</given-names></name><name><surname>Capanu</surname><given-names>M</given-names></name><name><surname>Salo-Mullen</surname><given-names>E</given-names></name><name><surname>Arnold</surname><given-names>AG</given-names></name><name><surname>Yu</surname><given-names>KH</given-names></name><name><surname>Varghese</surname><given-names>AM</given-names></name><name><surname>Kelsen</surname><given-names>DP</given-names></name><name><surname>Brenner</surname><given-names>R</given-names></name><name><surname>Kaufmann</surname><given-names>E</given-names></name><name><surname>Ravichandran</surname><given-names>V</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><name><surname>Klimstra</surname><given-names>DS</given-names></name><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Tjan</surname><given-names>C</given-names></name><name><surname>Covington</surname><given-names>C</given-names></name><name><surname>Maynard</surname><given-names>H</given-names></name><name><surname>Allen</surname><given-names>PJ</given-names></name><name><surname>Askan</surname><given-names>G</given-names></name><name><surname>Leach</surname><given-names>SD</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>CA</given-names></name><name><surname>Robson</surname><given-names>ME</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Stadler</surname><given-names>ZK</given-names></name><name><surname>O’Reilly</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms</article-title><source>Journal of the National Cancer Institute</source><volume>110</volume><fpage>1067</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1093/jnci/djy024</pub-id><pub-id pub-id-type="pmid">29506128</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McWilliams</surname><given-names>RR</given-names></name><name><surname>Wieben</surname><given-names>ED</given-names></name><name><surname>Rabe</surname><given-names>KG</given-names></name><name><surname>Pedersen</surname><given-names>KS</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Sicotte</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling</article-title><source>European Journal of Human Genetics</source><volume>19</volume><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2010.198</pub-id><pub-id pub-id-type="pmid">21150883</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McWilliams</surname><given-names>RR</given-names></name><name><surname>Wieben</surname><given-names>ED</given-names></name><name><surname>Chaffee</surname><given-names>KG</given-names></name><name><surname>Antwi</surname><given-names>SO</given-names></name><name><surname>Raskin</surname><given-names>L</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Highsmith</surname><given-names>WE</given-names></name><name><surname>Colon-Otero</surname><given-names>G</given-names></name><name><surname>Khanna</surname><given-names>LG</given-names></name><name><surname>Permuth</surname><given-names>JB</given-names></name><name><surname>Olson</surname><given-names>JE</given-names></name><name><surname>Frucht</surname><given-names>H</given-names></name><name><surname>Genkinger</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Blot</surname><given-names>WJ</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Almada</surname><given-names>LL</given-names></name><name><surname>Fernandez-Zapico</surname><given-names>ME</given-names></name><name><surname>Sicotte</surname><given-names>H</given-names></name><name><surname>Pedersen</surname><given-names>KS</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>27</volume><fpage>1364</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-17-1065</pub-id><pub-id pub-id-type="pmid">30038052</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>PJ</given-names></name><name><surname>Duraisamy</surname><given-names>S</given-names></name><name><surname>Newell</surname><given-names>JA</given-names></name><name><surname>Chan</surname><given-names>PA</given-names></name><name><surname>Tie</surname><given-names>MM</given-names></name><name><surname>Rogers</surname><given-names>AE</given-names></name><name><surname>Ankuda</surname><given-names>CK</given-names></name><name><surname>von Walstrom</surname><given-names>GM</given-names></name><name><surname>Bond</surname><given-names>JP</given-names></name><name><surname>Greenblatt</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Classifying variants of CDKN2A using computational and laboratory studies</article-title><source>Human Mutation</source><volume>32</volume><fpage>900</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1002/humu.21504</pub-id><pub-id pub-id-type="pmid">21462282</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>PKS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>KJ</given-names></name><name><surname>Shao</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Tsang</surname><given-names>YH</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Bhavana</surname><given-names>VH</given-names></name><name><surname>Tran</surname><given-names>R</given-names></name><name><surname>Soewito</surname><given-names>S</given-names></name><name><surname>Minussi</surname><given-names>DC</given-names></name><name><surname>Moreno</surname><given-names>D</given-names></name><name><surname>Kong</surname><given-names>K</given-names></name><name><surname>Dogruluk</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Tokheim</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>DC</given-names></name><name><surname>Johnson</surname><given-names>AM</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Ip</surname><given-names>CKM</given-names></name><name><surname>Ju</surname><given-names>Z</given-names></name><name><surname>Wester</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Vellano</surname><given-names>CP</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Karchin</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Cheung</surname><given-names>LWT</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>KR</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Scott</surname><given-names>KL</given-names></name><name><surname>Yi</surname><given-names>S</given-names></name><name><surname>Sahni</surname><given-names>N</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Systematic Functional Annotation of Somatic Mutations in Cancer</article-title><source>Cancer Cell</source><volume>33</volume><fpage>450</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.01.021</pub-id><pub-id pub-id-type="pmid">29533785</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>N</given-names></name><name><surname>Bale</surname><given-names>S</given-names></name><name><surname>Bick</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><name><surname>Grody</surname><given-names>WW</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Lyon</surname><given-names>E</given-names></name><name><surname>Spector</surname><given-names>E</given-names></name><name><surname>Voelkerding</surname><given-names>K</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><collab>ACMG Laboratory Quality Assurance Committee</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title><source>Genetics in Medicine</source><volume>17</volume><fpage>405</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id><pub-id pub-id-type="pmid">25741868</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>NJ</given-names></name><name><surname>Norris</surname><given-names>AL</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><name><surname>Bondy</surname><given-names>ML</given-names></name><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Kurtz</surname><given-names>RC</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>Schwartz</surname><given-names>AG</given-names></name><name><surname>Stoffel</surname><given-names>E</given-names></name><name><surname>Syngal</surname><given-names>S</given-names></name><name><surname>Zogopoulos</surname><given-names>G</given-names></name><name><surname>Ali</surname><given-names>SZ</given-names></name><name><surname>Axilbund</surname><given-names>J</given-names></name><name><surname>Chaffee</surname><given-names>KG</given-names></name><name><surname>Chen</surname><given-names>Y-C</given-names></name><name><surname>Cote</surname><given-names>ML</given-names></name><name><surname>Childs</surname><given-names>EJ</given-names></name><name><surname>Douville</surname><given-names>C</given-names></name><name><surname>Goes</surname><given-names>FS</given-names></name><name><surname>Herman</surname><given-names>JM</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>C</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>Makohon-Moore</surname><given-names>A</given-names></name><name><surname>McCombie</surname><given-names>RW</given-names></name><name><surname>McMahon</surname><given-names>KW</given-names></name><name><surname>Niknafs</surname><given-names>N</given-names></name><name><surname>Parla</surname><given-names>J</given-names></name><name><surname>Pirooznia</surname><given-names>M</given-names></name><name><surname>Potash</surname><given-names>JB</given-names></name><name><surname>Rhim</surname><given-names>AD</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wolfgang</surname><given-names>CL</given-names></name><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Zandi</surname><given-names>PP</given-names></name><name><surname>Goggins</surname><given-names>M</given-names></name><name><surname>Karchin</surname><given-names>R</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Klein</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer</article-title><source>Cancer Discovery</source><volume>6</volume><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0402</pub-id><pub-id pub-id-type="pmid">26658419</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>M</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><name><surname>Beach</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4</article-title><source>Nature</source><volume>366</volume><fpage>704</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1038/366704a0</pub-id><pub-id pub-id-type="pmid">8259215</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shindo</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Suenaga</surname><given-names>M</given-names></name><name><surname>Fesharakizadeh</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>C</given-names></name><name><surname>Macgregor-Das</surname><given-names>A</given-names></name><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Witmer</surname><given-names>PD</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>TJ</given-names></name><name><surname>Navarro Almario</surname><given-names>JA</given-names></name><name><surname>Brant</surname><given-names>A</given-names></name><name><surname>Borges</surname><given-names>M</given-names></name><name><surname>Ford</surname><given-names>M</given-names></name><name><surname>Barkley</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Weiss</surname><given-names>MJ</given-names></name><name><surname>Wolfgang</surname><given-names>CL</given-names></name><name><surname>Roberts</surname><given-names>NJ</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Klein</surname><given-names>AP</given-names></name><name><surname>Goggins</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma</article-title><source>Journal of Clinical Oncology</source><volume>35</volume><fpage>3382</fpage><lpage>3390</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.72.3502</pub-id><pub-id pub-id-type="pmid">28767289</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cancer statistics, 2020</article-title><source>CA</source><volume>70</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21590</pub-id><pub-id pub-id-type="pmid">31912902</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhi</surname><given-names>AD</given-names></name><name><surname>George</surname><given-names>B</given-names></name><name><surname>Greenbowe</surname><given-names>JR</given-names></name><name><surname>Chung</surname><given-names>J</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Klempner</surname><given-names>SJ</given-names></name><name><surname>Hendifar</surname><given-names>A</given-names></name><name><surname>Milind</surname><given-names>JM</given-names></name><name><surname>Golan</surname><given-names>T</given-names></name><name><surname>Brand</surname><given-names>RE</given-names></name><name><surname>Zureikat</surname><given-names>AH</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Schrock</surname><given-names>AB</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Bahary</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers</article-title><source>Gastroenterology</source><volume>156</volume><fpage>2242</fpage><lpage>2253</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.02.037</pub-id><pub-id pub-id-type="pmid">30836094</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirivatanauksorn</surname><given-names>V</given-names></name><name><surname>Sirivatanauksorn</surname><given-names>Y</given-names></name><name><surname>Gorman</surname><given-names>PA</given-names></name><name><surname>Davidson</surname><given-names>JM</given-names></name><name><surname>Sheer</surname><given-names>D</given-names></name><name><surname>Moore</surname><given-names>PS</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>PAW</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping</article-title><source>International Journal of Cancer</source><volume>91</volume><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1002/1097-0215(200002)9999:9999&lt;::aid-ijc1049&gt;3.3.co;2-3</pub-id><pub-id pub-id-type="pmid">11169959</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>SA</given-names></name><name><surname>Dykxhoorn</surname><given-names>DM</given-names></name><name><surname>Palliser</surname><given-names>D</given-names></name><name><surname>Mizuno</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>EY</given-names></name><name><surname>An</surname><given-names>DS</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>ISY</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name><name><surname>Novina</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Lentivirus-delivered stable gene silencing by RNAi in primary cells</article-title><source>RNA</source><volume>9</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1261/rna.2192803</pub-id><pub-id pub-id-type="pmid">12649500</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoffel</surname><given-names>EM</given-names></name><name><surname>McKernin</surname><given-names>SE</given-names></name><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Canto</surname><given-names>M</given-names></name><name><surname>Goggins</surname><given-names>M</given-names></name><name><surname>Moravek</surname><given-names>C</given-names></name><name><surname>Nagarajan</surname><given-names>A</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><name><surname>Simeone</surname><given-names>DM</given-names></name><name><surname>Yurgelun</surname><given-names>M</given-names></name><name><surname>Khorana</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion</article-title><source>Journal of Clinical Oncology</source><volume>37</volume><fpage>153</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.01489</pub-id><pub-id pub-id-type="pmid">30457921</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer</article-title><source>PNAS</source><volume>115</volume><fpage>4767</fpage><lpage>4772</lpage><pub-id pub-id-type="doi">10.1073/pnas.1720588115</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasen</surname><given-names>H</given-names></name><name><surname>Ibrahim</surname><given-names>I</given-names></name><name><surname>Ponce</surname><given-names>CG</given-names></name><name><surname>Slater</surname><given-names>EP</given-names></name><name><surname>Matthäi</surname><given-names>E</given-names></name><name><surname>Carrato</surname><given-names>A</given-names></name><name><surname>Earl</surname><given-names>J</given-names></name><name><surname>Robbers</surname><given-names>K</given-names></name><name><surname>van Mil</surname><given-names>AM</given-names></name><name><surname>Potjer</surname><given-names>T</given-names></name><name><surname>Bonsing</surname><given-names>BA</given-names></name><name><surname>de Vos Tot Nederveen Cappel</surname><given-names>WH</given-names></name><name><surname>Bergman</surname><given-names>W</given-names></name><name><surname>Wasser</surname><given-names>M</given-names></name><name><surname>Morreau</surname><given-names>H</given-names></name><name><surname>Klöppel</surname><given-names>G</given-names></name><name><surname>Schicker</surname><given-names>C</given-names></name><name><surname>Steinkamp</surname><given-names>M</given-names></name><name><surname>Figiel</surname><given-names>J</given-names></name><name><surname>Esposito</surname><given-names>I</given-names></name><name><surname>Mocci</surname><given-names>E</given-names></name><name><surname>Vazquez-Sequeiros</surname><given-names>E</given-names></name><name><surname>Sanjuanbenito</surname><given-names>A</given-names></name><name><surname>Muñoz-Beltran</surname><given-names>M</given-names></name><name><surname>Montans</surname><given-names>J</given-names></name><name><surname>Langer</surname><given-names>P</given-names></name><name><surname>Fendrich</surname><given-names>V</given-names></name><name><surname>Bartsch</surname><given-names>DK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>2010</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.0730</pub-id><pub-id pub-id-type="pmid">27114589</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yakobson</surname><given-names>E</given-names></name><name><surname>Shemesh</surname><given-names>P</given-names></name><name><surname>Azizi</surname><given-names>E</given-names></name><name><surname>Winkler</surname><given-names>E</given-names></name><name><surname>Lassam</surname><given-names>N</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Brookes</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Lotem</surname><given-names>M</given-names></name><name><surname>Zlotogorski</surname><given-names>A</given-names></name><name><surname>Landau</surname><given-names>M</given-names></name><name><surname>Safro</surname><given-names>M</given-names></name><name><surname>Shafir</surname><given-names>R</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name><name><surname>Peretz</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families</article-title><source>European Journal of Human Genetics</source><volume>8</volume><fpage>590</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/sj.ejhg.5200505</pub-id><pub-id pub-id-type="pmid">10951521</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamato</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>SMAD4 genes in 15 human pancreatic cancer cell lines</article-title><source>Oncology Reports</source><volume>8</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.3892/or.8.1.89</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>DB</given-names></name><name><surname>Rabe</surname><given-names>KG</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Syngal</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>AG</given-names></name><name><surname>Goggins</surname><given-names>MG</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Cote</surname><given-names>ML</given-names></name><name><surname>McWilliams</surname><given-names>RR</given-names></name><name><surname>Roberts</surname><given-names>NJ</given-names></name><name><surname>Cannon-Albright</surname><given-names>LA</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Moyes</surname><given-names>K</given-names></name><name><surname>Wenstrup</surname><given-names>RJ</given-names></name><name><surname>Hartman</surname><given-names>A-R</given-names></name><name><surname>Seminara</surname><given-names>D</given-names></name><name><surname>Klein</surname><given-names>AP</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study</article-title><source>Genetics in Medicine</source><volume>17</volume><fpage>569</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1038/gim.2014.153</pub-id><pub-id pub-id-type="pmid">25356972</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Rensing</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effects of two different high-fidelity DNA polymerases on genetic analysis of the cyanobacterial community structure in a subtropical deep freshwater reservoir</article-title><source>Archives of Microbiology</source><volume>199</volume><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/s00203-016-1284-7</pub-id><pub-id pub-id-type="pmid">27591881</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71137.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lou</surname><given-names>Emil</given-names></name><role>Reviewing Editor</role><aff><institution>University of Minnesota</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for resubmitting your work entitled &quot;Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of unknown significance&quot; for further consideration by <italic>eLife</italic>. Your article has been reviewed by 2 reviewers, one of whom is member of our Board of Reviewing Editors and the evaluation has been overseen by Wafik El-Deiry as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p><italic>Reviewer #1:</italic></p><p>The investigators postulated that some variants of uncertain significance (VUS) of CDKN2A have been misclassified, and that some proportion may be in fact be deleterious and possibly pathogenic in carcinogenesis of pancreatic ductal adenocarcinoma (PDAC). in vitro analysis of cell proliferation of 29 known VUSs was performed, and the authors report that &gt;40% of these variants are functionally deleterious.</p><p>CDKN2A encodes a tumor suppressor as well as an important regulator of progression through the cell cycle. It has been extensively studied in epithelial carcinomas, including pancreatic ductal adenocarcinomas (PDAC). The concept that a significant number of previously reported variants of this gene may not be as benign has important implications for understanding etiology and downstream molecular effects and tumoral progression of this cancer, especially in the albeit relatively small number of patients who harbor germline variants that may be important in driving pancreatic cancer development. The study is well-written and leverages an established and validated in vitro cell proliferation assay from this lab.</p><p>1. The information redesignating 40% of the VUS as functionally deleterious and possibly pathogenic is applied to external datasets. Did the investigators gain access to the raw data from the authors of the cited published works, or were the reassignments based on available information that was published? It would be important to access and confirm the raw data.</p><p>2. Application to an internal dataset of tumor samples would affirm the conclusions made from the in vitro validation steps.</p><p>3. The use of only a single PDAC cell line is a limitation that tempers the conclusions of the study [PANC-1 is a hypertriploid cell line; what is the effect in relation to CDKN2A?].The in vitro analysis should be performed on at least three cell lines to control for other differences between cell lines. This work would strengthen the argument, as the premise of the study is to extend the finding to in vivo/human PDAC, with implications that the reassigned germline VUSs are more pathogenic in humans than previously thought.</p><p><italic>Reviewer #2:</italic></p><p>The study provides evidence of functionality of mutations present in pancreatic cancer, a dismal condition predicted be the second cause of cancer death by 2030. Specifically, the authors showed that mutations in CDKN2A associated with increased risk of developing pancreatic cancer have lost the ability to control cell growth.</p><p>The authors have functionally characterized CDKN2A mutations present in familial pancreatic cancer cases. The methodology used is for the most adequate to address the main goal of the study. Some of the deficiencies/weaknesses are associated with limitations of the pancreatic cancer model/methodologies and lack of side by side comparison with other known factors associated with increased risk of the disease as well as clinical correlations of these mutations.</p><p>To fully support the authors conclusions, the authors should</p><p>1) The Panc1 results should be repeated in two additional lines to avoid any cell line bias effect.</p><p>2) The cell growth analysis should be confirmed using a cell cycle analysis to define if the mutants lack the ability to control G1 progression.</p><p>3) The study should include side-by-side comparison with other know p16 mutations from familial cases.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71137.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>The investigators postulated that some variants of uncertain significance (VUS) of CDKN2A have been misclassified, and that some proportion may be in fact be deleterious and possibly pathogenic in carcinogenesis of pancreatic ductal adenocarcinoma (PDAC). in vitro analysis of cell proliferation of 29 known VUSs was performed, and the authors report that &gt;40% of these variants are functionally deleterious.</p><p>CDKN2A encodes a tumor suppressor as well as an important regulator of progression through the cell cycle. It has been extensively studied in epithelial carcinomas, including pancreatic ductal adenocarcinomas (PDAC). The concept that a significant number of previously reported variants of this gene may not be as benign has important implications for understanding etiology and downstream molecular effects and tumoral progression of this cancer, especially in the albeit relatively small number of patients who harbor germline variants that may be important in driving pancreatic cancer development. The study is well-written and leverages an established and validated in vitro cell proliferation assay from this lab.</p><p>1. The information redesignating 40% of the VUS as functionally deleterious and possibly pathogenic is applied to external datasets. Did the investigators gain access to the raw data from the authors of the cited published works, or were the reassignments based on available information that was published? It would be important to access and confirm the raw data.</p></disp-quote><p>We are happy to clarify. Several authors of this manuscript were also authors of the cited published works used to identify VUS for assay. These authors were extensively involved in the analysis and interpretation of these variant data. The cited studies included research next-generation sequencing (whole genome and gene-panel), Sanger sequencing, and CLIA approved clinical genetic testing that have high-confidence for single base substitution calls. As such, we are confident in the VUS calls used in this manuscript.</p><disp-quote content-type="editor-comment"><p>2. Application to an internal dataset of tumor samples would affirm the conclusions made from the in vitro validation steps.</p></disp-quote><p>We thank the reviewer for their suggestion. We agree that analysis of tumor samples might provide additional evidence to validate functional characterizations. Unfortunately, only ~10% of patients with pancreatic ductal adenocarcinoma undergo resection and have tissue available for correlative studies. We were unable to identify any tumor tissue for patients with functionally deleterious or potentially functionally deleterious VUS where additional studies would be informative, for example, somatic <italic>CDKN2A</italic> loss-of-heterozygosity with retention of the deleterious variant (supporting evidence) or somatic loss of the deleterious variant (refuting evidence). However, even without tumor samples, we present additional experimental evidence to support our functional characterizations (see below).</p><disp-quote content-type="editor-comment"><p>3. The use of only a single PDAC cell line is a limitation that tempers the conclusions of the study [PANC-1 is a hypertriploid cell line; what is the effect in relation to CDKN2A?].The in vitro analysis should be performed on at least three cell lines to control for other differences between cell lines. This work would strengthen the argument, as the premise of the study is to extend the finding to in vivo/human PDAC, with implications that the reassigned germline VUSs are more pathogenic in humans than previously thought.</p></disp-quote><p>We are happy to provide the additional experimental data requested by the reviewer. We have now assayed selected <italic>CDKN2A</italic> variants (pathogenic, benign, and VUS) in two additional cell lines (MIA PaCa-2 and AsPC-1). Reassuringly, no VUS with a functionally deleterious or potentially functionally deleterious classification in one cell line had a functionally neutral or potentially functionally neutral classification in the other cell lines tested. Furthermore, cell cycle analysis to determine the distribution of cells in each stage of the cell cycle provides support for our functional classifications. These additional data indicate that our functional classifications are robust to cell lines specific effects included ploidy and genetic background.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>The study provides evidence of functionality of mutations present in pancreatic cancer, a dismal condition predicted be the second cause of cancer death by 2030. Specifically, the authors showed that mutations in CDK2A associated with increased risk of developing pancreatic cancer have lost the ability to control cell growth.</p><p>The authors have functionally characterized CDK2A mutations present in familial pancreatic cancer cases. The methodology used is for the most adequate to address the main goal of the study. Some of the deficiencies/weaknesses are associated with limitations of the pancreatic cancer model/methodologies and lack of side by side comparison with other known factors associated with increased risk of the disease as well as clinical correlations of these mutations.</p><p>To fully support the authors conclusions, the authors should</p><p>1) The Panc1 results should be repeated in two additional lines to avoid any cell line bias effect.</p></disp-quote><p>We are happy to provide the additional experimental data requested by the reviewer. We have now assayed selected <italic>CDKN2A</italic> variants (pathogenic, benign, and VUS) in two additional cell lines (MIA PaCa-2 and AsPC-1). Reassuringly, no VUS with a functionally deleterious or potentially functionally deleterious classification in one cell line had a functionally neutral or potentially functionally neutral classification in the other cell lines tested.</p><disp-quote content-type="editor-comment"><p>2) The cell growth analysis should be confirmed using a cell cycle analysis to define if the mutants lack the ability to control G1 progression.</p></disp-quote><p>We thank the reviewer for this suggestion. We have completed cell cycle analysis to determine the distribution of cells in each stage of the cell cycle for each assayed variant in PANC-1 cells. These data provide clear support for our functional classifications and indicate that expression of pathogenic or functionally deleterious variants do not inhibit cell cycle progression. Specifically, pathogenic and functionally deleterious variants had a lower percentage of cells in G1 phase and a higher percentage of cells in G2/M phase compared to benign and functionally neutral variants.</p><disp-quote content-type="editor-comment"><p>3) The study should include side-by-side comparison with other know p16 mutations from familial cases.</p></disp-quote><p>We are grateful for the opportunity to clarify. The majority of pathogenic germline variants tested in our assay were either identified in patients with familial pancreatic cancer (5 of 9 variants) or in patients with pancreatic adenocarcinoma (2 of 9). Furthermore, these variants were classified as pathogenic using American College of Medical Genetics variant interpretation guidelines. As such, our assay has broad applicability to patients with pancreatic cancer.</p></body></sub-article></article>